The Alzheimer's Association International Conference (AAIC) 2026 represents the premier annual gathering for Alzheimer's and dementia research. This year's conference featured groundbreaking presentations on disease mechanisms, novel therapeutic approaches, biomarker advances, and prevention strategies. The scientific program encompassed over 2,000 presentations across multiple tracks, attracting researchers, clinicians, and industry partners from around the world.
The 2026 conference emphasized several key research areas:
- Amyloid and Tau Biology: New insights into amyloid precursor protein (APP) processing, tau phosphorylation mechanisms, and propagation pathways
- Microglial Biology: TREM2 variants, DAM (disease-associated microglia) phenotypes, and neuroimmune crosstalk
- Biomarker Advances: Blood-based biomarkers (p-tau217, p-tau181,NfL), PET imaging tracers, and CSF diagnostics
- Therapeutic Pipeline: Update on monoclonal antibodies, small molecules, gene therapies, and combinatorial approaches
- Prevention Strategies: Lifestyle interventions, cardiovascular risk modification, and early intervention approaches
The conference featured several notable keynote addresses covering:
- Precision Medicine in Alzheimer's: Dr. Reisa Sperling (Harvard Medical School) presented on biomarker-guided therapeutic approaches and the shift toward preclinical intervention
- Neuroimmune Pathways: Dr. Michael Heneka (University of Bonn) discussed inflammasome activation and microglial modulation strategies
- Single-Cell Genomics: Dr. Li-Huei Tsai (MIT) presented single-nucleus transcriptomics findings from human brain tissue
- Global Dementia Prevention: Dr. Gill Livingston (UCL) reviewed modifiable risk factors and implementation strategies
The basic science track covered fundamental mechanisms of neurodegeneration:
¶ Protein Aggregation and Clearance
¶ Synaptic Dysfunction and Plasticity
- Synaptic vesicle cycle alterations
- NMDA receptor signaling abnormalities
- Dendritic spine loss mechanisms
- Network connectivity disruption
- APOE ε4 carrier status and risk modification
- TREM2 coding variants and microglial function
- Rare variant discovery in early-onset AD
- Polygenic risk score applications
- Microglia: TREM2 biology, DAM phenotypes, complement system activation
- Astrocytes: Reactive astrogliosis, metabolic support loss, glutamate homeostasis
- Oligodendrocytes: Myelin degradation, white matter vulnerability
- Inflammasome activation (NLRP3, AIM2)
- Cytokine signaling (IL-1β, IL-6, TNF-α)
- Complement system involvement in synapse elimination
- T cell infiltration and peripheral immune crosstalk
The clinical research track addressed translational and clinical aspects:
- Blood-based biomarker validation (p-tau217, p-tau181, NfL, GFAP)
- PET imaging advances (flortaucipir, florbetapir, novel tracers)
- CSF biomarker interpretation and standardization
- Digital biomarkers and wearable technologies
- Computerized cognitive testing platforms
- Remote monitoring and telehealth assessment
- Sensitive outcome measures for preclinical populations
- Cultural adaptation and language validation
- Enrichment strategies based on biomarker status
- Bayesian adaptive designs in AD trials
- Diversity and inclusion in clinical research
- Real-world evidence and observational studies
¶ Prevention and Early Intervention
- Lifestyle modification trials (FINGER, SPRINT-MIND)
- Multimodal intervention approaches
- Early detection and preclinical intervention
- Risk factor modification strategies
The therapeutics track showcased the drug development pipeline:
- Monoclonal antibodies targeting amyloid (lecanemab, donanemab)
- Anti-tau immunotherapies and small molecules
- Neuroprotective and regenerative approaches
- Combination therapy strategies
- Synaptic stabilization compounds
- Neuroinflammation modulators
- Metabolic enhancers
- Chaperone inducers
- GLP-1 receptor agonists for neuroprotection
- Metformin and metabolic modulators
- Anti-inflammatory agents
- Cardiovascular drugs with cognitive benefits
¶ Prevention and Risk Reduction
- Cardiovascular health and blood pressure management
- Type 2 diabetes and metabolic syndrome
- Physical activity and exercise interventions
- Cognitive reserve and education
- Diet (MIND diet, Mediterranean diet)
- Sleep optimization
- Social engagement and cognitive stimulation
- Sensory impairment correction (hearing loss)
Each scientific session runs approximately 90 minutes and includes:
- Presentations: 3-4 presentations of 15-20 minutes each
- Panel Discussion: Expert Q&A and debate
- Poster Sessions: Interactive research presentations
- Networking Opportunities: Collaboration and partnership building
¶ Gene and Protein Pages